Perlecan is essential for cartilage and cephalic development

Nature Genetics

Volumn 23, Issue 3, 1999, Pages 354-358

  Arikawa Hirasawa, Eri ^a   Watanabe, Hideto ^a   Takami, Hiroya ^a   Hassell, John R ^b   Yamada, Yoshihiko ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^b SHRINERS HOSPITALS FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN FIBER; GLYCOSAMINOGLYCAN; PERLECAN; SCLEROPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASEMENT MEMBRANE; BONE DEVELOPMENT; BONE DYSPLASIA; BRAIN DEVELOPMENT; CONTROLLED STUDY; CRANIOFACIAL MALFORMATION; ENCHONDRAL OSSIFICATION; EXTRACELLULAR MATRIX; GENE DISRUPTION; GENE MUTATION; MOUSE; NEWBORN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION;

ABNORMALITIES, MULTIPLE; ANIMALS; ANIMALS, NEWBORN; CARTILAGE; CELL DIFFERENTIATION; CELL DIVISION; CHONDROCYTES; EXTRACELLULAR MATRIX PROTEINS; GENE DELETION; GENE EXPRESSION; GLYCOPROTEINS; GROWTH PLATE; HEAD; HEPARAN SULFATE PROTEOGLYCANS; HEPARITIN SULFATE; HUMANS; MICE; MICE, TRANSGENIC; MUTAGENESIS, INSERTIONAL; PROTEIN-TYROSINE KINASES; PROTEOGLYCANS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RECEPTORS, FIBROBLAST GROWTH FACTOR; RNA, MESSENGER; THANATOPHORIC DYSPLASIA;

ANIMALIA; MAMMALIA; RODENTIA;

EID: 0032726952     PISSN: 10614036     EISSN: None     Source Type: Journal    
DOI: 10.1038/15537     Document Type: Article

References (30)

1. Noonan, D.M. et al. The complete sequence of perlecan, a basement membrane heparan sulfate proteoglycan, reveals extensive similarity with laminin A chain, low density lipoprotein-receptor, and the neural cell adhesion molecule. J. Biol. Chem. 266, 22939-22947 (1991).
2. lozzo, R.V., Cohen, I.R., Grassel, S. & Murdoch, A.D. The biology of perlecan: the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem. J. 302, 625-639 (1994).
3. Aviezer, D. et al. Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis. Cell 79, 1005-1013 (1994).
4. SundarRaj, N., Fite, D., Ledbetter, S., Chakravarti, S. & Hassell, J.R. Perlecan is a component of cartilage matrix and promotes chondrocyte attachment. J. Cell. Sci. 108, 2663-2672 (1995).
5. Handler, M., Yurchenco, P.D. & lozzo, R.V. Developmental expression of perlecan during murine embryogenesis. Dev. Dyn. 210, 130-145 (1997).
6. Morriss-Kay, G. & Tucket, F. Early events in mammalian craniofacial morphogenesis. J. Craniofac. Genet Dev. Biol. 11, 181-191 (1991).
7. Tavormina, P.L. et al. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. Nature Genet 9, 321-328 (1995).
8. Norton, W.A. Fibroblast growth factor receptor 3 and the human chondrodysplasias. Curr. Opin. Pediatr. 9, 437-442 (1997).
9. Weber, M., Johannisson, T., Thomsen, M., Rehder, H. & Niethard, F.U. Thanatophoric dysplasia type I: new radiologic, morphologic, and histologic aspects toward the exact definition of the disorder. J. Pediatr. Orthop. B 7, 1-9 (1998).
10. Naski, M.C., Colvin, J.S., Coffin, J.D. & Ornitz, D.M. Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. Development 125, 4977-4988 (1998).
11. Li, C. et al. A lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors. Hum. Mol. Genet. 8, 35-44 (1999).
12. Wilcox, W.R. et al. Molecular, radiologic, and histopathologic correlations in thanatophoric dysplasia. Am. J. Med. Genet. 78, 274-281 (1998).
13. Naski, M.C., Wang, Q., Xu, J. & Ornitz, D.M. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Nature Genet 13, 233-237 (1996).
14. Chuang, P.T. & McMahon, A.P. Vertebrate Hedgehog signalling modulated by induction of a Hedgehog-binding protein. Nature 397, 617-621 (1999).
15. Aszodi, A., Pfeifer, A., Wendel, M., Hitipi, L. & Fassler, R. Mouse models for extracellular matrix diseases. J. Mol. Med. 76, 238-252 (1998).
16. Watanabe, H. & Yamada, Y. Mice lacking link protein develop dwarfism and craniofacial abnormalities. Nature Genet. 21, 225-229 (1999).
17. Deng, C., Wynshaw-Boris, A., Zhou, F., Kuo, A. & Leder, P. Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell 84, 911-921 (1996).
18. Ornoy, A., Adomian, G.E., Eteson, DJ., Burgeson, R.E. & Rimoin, D.L. The role of mesenchyme-like tissue in the pathogenesis of thanatophoric dysplasia. Am. J. Med. Genet. 21, 613-630 (1985).
19. Norton, W.A., Hood, O.J., Machado, MA, Ahmed, S. & Griffey, E.S. Abnormal ossification in thanatophoric dysplasia. Bone 9, 53-61 (1988).
20. Vortkamp, A. et al. Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein. Science 273, 613-622 (1996).
21. Colvin, J.S., Bohne, B.A., Harding, G.W., McEwen, D.G. & Ornitz, D.M. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3. Nature Genet. 12, 390-397 (1996).
22. Su, W.C. et al. Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. Nature 386, 288-292 (1997).
23. Sahni, M. et al. FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. Genes. Dev. 13, 1361-1366 (1999).
24. Ornitz, D.M. et al. FGF binding and FGF receptor activation by synthetic heparan-derived di- and trisaccharides. Science 268, 432-436 (1995).
25. Delezoide, A.L. et al. Abnormal FGFR3 expression in cartilage of thanatophoric dysplasia fetuses. Hum. mol. Genet. 6, 1899-1906 (1997).
26. Aviezer, D., Iozzo, R.V., Noonan, D.M. & Yayon, A. Suppression of autocrine and paracrine functions of basic fibroblast growth factor by stable expression of perlecan antisense cDNA. Mol. Cell. Biol. 17, 1938-1946 (1997).
27. Tybulewicz, V.L., Crawford, C.E., Jackson, P.K., Bronson, R.T. & Mulligan, U.C. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 65, 1153-1163 (1991).
28. Peters, P.W. Double staining of fetal skeletons for cartilage and bone, in Methods in Prenatal Toxicology (eds Neubert, D. et al.) 153-154 (Thieme, Stuttgart, 1977).
29. Arahata, K. et al. Immunostaining of skeletal and cardiac muscle surface membrane with antibody against Duchenne muscular dystrophy peptide. Nature 333, 861-863 (1988).
30. Harris, M.J. & Juriloff, D.M. Genetic landmarks for defects in mouse neural tube closure. Teratology 56, 177-187 (1997).